Galderma Labs Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GALDERMA LABS, and when can generic versions of GALDERMA LABS drugs launch?
GALDERMA LABS has twenty-eight approved drugs.
There are fifty-eight US patents protecting GALDERMA LABS drugs.
There are four hundred and five patent family members on GALDERMA LABS drugs in thirty-seven countries and one hundred and seventy-eight supplementary protection certificates in eighteen countries.
Summary for Galderma Labs
International Patents: | 405 |
US Patents: | 58 |
Tradenames: | 19 |
Ingredients: | 16 |
NDAs: | 28 |
Drugs and US Patents for Galderma Labs
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Galderma Labs Lp | EPIDUO | adapalene; benzoyl peroxide | GEL;TOPICAL | 022320-001 | Dec 8, 2008 | AB | RX | Yes | Yes | 8,129,362 | ⤷ Try a Trial | ⤷ Try a Trial | |||
Galderma Labs Lp | ORACEA | doxycycline | CAPSULE;ORAL | 050805-001 | May 26, 2006 | AB | RX | Yes | Yes | 8,206,740 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Galderma Labs Lp | DIFFERIN | adapalene | GEL;TOPICAL | 021753-001 | Jun 19, 2007 | AB | RX | Yes | Yes | 7,579,377 | ⤷ Try a Trial | ⤷ Try a Trial | |||
Galderma Labs Lp | ORACEA | doxycycline | CAPSULE;ORAL | 050805-001 | May 26, 2006 | AB | RX | Yes | Yes | 8,394,406 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Galderma Labs
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Galderma Labs Lp | ORACEA | doxycycline | CAPSULE;ORAL | 050805-001 | May 26, 2006 | 9,241,946 | ⤷ Try a Trial |
Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | 8,080,530 | ⤷ Try a Trial |
Galderma Labs | EPIDUO FORTE | adapalene; benzoyl peroxide | GEL;TOPICAL | 207917-001 | Jul 15, 2015 | 8,936,800 | ⤷ Try a Trial |
Galderma Labs Lp | TRI-LUMA | fluocinolone acetonide; hydroquinone; tretinoin | CREAM;TOPICAL | 021112-001 | Jan 18, 2002 | 7,915,243 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GALDERMA LABS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Topical Gel | 0.33% | ➤ Subscribe | 2014-12-15 |
➤ Subscribe | Gel | 0.3%/2.5% | ➤ Subscribe | 2016-05-04 |
➤ Subscribe | Spray | 0.05% | ➤ Subscribe | 2008-09-29 |
➤ Subscribe | Delayed-release Capsules | 40 mg | ➤ Subscribe | 2008-12-11 |
➤ Subscribe | Cream | 1% | ➤ Subscribe | 2016-12-30 |
➤ Subscribe | Topical Gel | 1% | ➤ Subscribe | 2008-10-21 |
➤ Subscribe | Lotion | 0.05% | ➤ Subscribe | 2006-03-27 |
➤ Subscribe | Topical Shampoo | 0.05% | ➤ Subscribe | 2008-01-09 |
➤ Subscribe | Topical Gel | 0.30% | ➤ Subscribe | 2009-09-15 |
➤ Subscribe | Gel | 0.1%/2.5% | ➤ Subscribe | 2011-12-30 |
International Patents for Galderma Labs Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Spain | 2371945 | ⤷ Try a Trial |
Slovenia | 1831149 | ⤷ Try a Trial |
Spain | 2812532 | ⤷ Try a Trial |
Argentina | 057866 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Galderma Labs Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1831149 | CR 2020 00027 | Denmark | ⤷ Try a Trial | PRODUCT NAME: TRIFAROTEN, EVENTUELT I FORM AF ET SALT DERAF; NAT. REG. NO/DATE: 61878 20200120; FIRST REG. NO/DATE: UK PL 10590/0071 20200113 |
0454511 | SPC/GB98/037 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE) (GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS.; REGISTERED: CH 54 250.02 19970815; UK EU/1/97/046/001 19970827; UK EU/1/97/046/002 19970827; UK EU/1/97/046/003 19970827; UK EU/1/97/046/004 19970827; UK EU/1/97/046/005 19970827; UK EU/1/97/046/006 19970827; UK EU/1/97/046/007 19970827; UK EU/1/97/046/008 19970827; UK EU/1/97/046/009 19970827 |
1620113 | CR 2015 00045 | Denmark | ⤷ Try a Trial | PRODUCT NAME: LVERMECTIN (22,23-DIHYDROAVERMECTIN B1 A + 22,23-DIHYDROAVERMECTIN B1 B); NAT. REG. NO/DATE: 54123 20150422; FIRST REG. NO/DATE: MT MA 117/01101 20150402 |
1631293 | CR 2014 00031 | Denmark | ⤷ Try a Trial | PRODUCT NAME: BRIMONIDIN OG ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER BRIMONIDIN TARTRAT; REG. NO/DATE: EU/1/13/904/001-003 20140221 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.